Journal Mobile Options
Table of Contents
35, No. 7-8, 2012
Issue release date: August 2012
Add to my selection Citation Download
Onkologie 2012;35:427–431
(DOI:10.1159/000340072)
Original Article · Originalarbeit

Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer

Idelevich E.a · Kashtan H.b · Klein Y.b · Buevich V.b · Baruch N.B.a · Dinerman M.a · Tokar M.d · Kundel Y.c · Brenner B.c
aInstitute of Oncology, bDepartment of Surgery, Kaplan Medical Center, Rehovot and the Faculty of Medicine, The Hebrew University of Jerusalem, cInstitute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tiqva and the Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, dDepartment of Oncology, Soroka Medical Center, Beer Sheva, Israel Onkologie 2012;35:427–431 (DOI:10.1159/000340072)

Abstract

Background: We investigated the efficacy and tolerability of cisplatin and 5-fluorouracil (5-FU) plus bevacizumab as neoadjuvant therapy for patients with locally advanced resectable esophageal cancer. Patients and Methods: In this prospective phase II study, 22 patients with adenocarcinoma and 6 with squamous cell carcinoma received 2 4-day cycles of bevacizumab 7.5 mg/kg followed by cisplatin 80 mg/m2 infusion on day 1 followed by 5-FU 1,000 mg/m2 as a 96-h continuous infusion on days 1–4, separated by a 3-week interval. Results: The response rate was 39%, the R0 resection rate was 43%, and the median overall survival (OS) was 17 months. The regimen was well tolerated, with the most common severe toxicities being venous thromboembolism (10%), nausea, and gastrointestinal bleeding (7% each). In 37 patients previously treated with cisplatin and 5-FU alone at our institution and thus serving as historical controls, the response rate was 30%, the R0 resection rate was 44%, and the median OS was 23 months. There was no statistically significant difference between the 2 groups of patients. Conclusion: Adding bevacizumab to cisplatin and 5-FU neoadjuvant chemotherapy was active and well tolerated but did not seem to improve the resection rate or OS compared with prior regimens, including the historical controls at our institution.

 goto top of outline Author Contacts

Dr. Efraim Idelevich, Institute of Oncology, Kaplan Medical Center, POB 1, 76100 Rehovot, Israel, Tel. +972 8944-1088, Fax -1088, Efraim_I@clalit.org.il


 goto top of outline Article Information

Published online: July 6, 2012
Number of Print Pages : 5


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 35, No. 7-8, Year 2012 (Cover Date: August 2012)

Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.